Global Hepatitis B Virus (HBV) Treatment Market
Global HBV market was valued at $eri2.8bn in 2015 and is forecast to grow at a modest CAGR of 1.8% between 2015 and 2024, reaching 2024 sales of $3.3bn.
Globally, 350 million people are living with Chronic Hepatitis B (CHB) infection currently. CHB affects up to 2.2 million people in the U.S. Because of the high incidence and risk of liver injury, CHB is a major global health and economic burden. Every year, close to a million people die due to CHB infection related complications including cirrhosis and hepatocellular carcinoma.
Despite the large number of patients with CHB worldwide, the current commercial opportunity is modest since the market in the U.S. and Europe is small, and the available treatments remain suboptimal. Existing therapies can slow disease progression, but cannot cure the chronic infection.
There are a number of HBV programs in clinical development. Gilead, Inovio, Roche, Altimune and Transgene are engaged in the development of therapeutic vaccines in HBV space. Many of the experimental therapies are still in early stage of development. and it is unclear if any have the potential to increase cure rates and revolutionize treatment.
“Bristol Myers, GSK, Merck, Gilead, Roche & Novartis are some of the key players in HBV market"